| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/CTR.12585 |
| P698 | PubMed publication ID | 26147308 |
| P50 | author | Jonathan Merola | Q57491302 |
| P2093 | author name string | David C Mulligan | |
| Peter S Yoo | |||
| AnnMarie Liapakis | |||
| P2860 | cites work | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 |
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial | Q28661700 | ||
| Liver fibrosis | Q29547449 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease | Q30312283 | ||
| Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis | Q33563333 | ||
| Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis | Q34065266 | ||
| Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. | Q34525065 | ||
| Cardiovascular morbidity and mortality after orthotopic liver transplantation | Q34581979 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis | Q35001746 | ||
| Mechanisms involved in the side effects of glucocorticoids | Q35003894 | ||
| Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. | Q35103678 | ||
| Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants | Q35535285 | ||
| A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma | Q36175047 | ||
| Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases | Q36288796 | ||
| Posttransplant metabolic syndrome | Q36446760 | ||
| Donor polymorphisms of toll-like receptor 4 associated with graft failure in liver transplant recipients | Q36456874 | ||
| Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation | Q37092562 | ||
| Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis | Q37122480 | ||
| Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis | Q37548563 | ||
| Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report | Q37613128 | ||
| Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease | Q37638636 | ||
| Pathology and biopsy assessment of non-alcoholic fatty liver disease | Q37749340 | ||
| The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. | Q37894169 | ||
| Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation | Q38022211 | ||
| Evolving aspects of liver transplantation for nonalcoholic steatohepatitis | Q38104949 | ||
| Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). | Q38175368 | ||
| Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. | Q38192013 | ||
| Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS‐1E beta‐cells | Q38341033 | ||
| The first Polish liver transplantation after Roux-en-Y gastric bypass surgery for morbid obesity: a case report and literature review. | Q38364839 | ||
| Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. | Q38447369 | ||
| Focal sparing of segment IV in fatty livers shown by sonography and CT: correlation with aberrant gastric venous drainage | Q39378945 | ||
| Pentoxifylline | Q40740262 | ||
| The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial | Q41172779 | ||
| Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 | ||
| Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. | Q42262646 | ||
| Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States | Q42616954 | ||
| Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. | Q42662677 | ||
| Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". | Q43205304 | ||
| Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease | Q43294932 | ||
| Hepatic decompensation after gastric bypass surgery for severe obesity | Q43481491 | ||
| Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. | Q43634298 | ||
| Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity | Q43685036 | ||
| Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis | Q43837544 | ||
| Outcome after liver transplantation for NASH cirrhosis | Q43888512 | ||
| Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events | Q44348839 | ||
| Long-term follow-up of patients with nonalcoholic fatty liver | Q44431564 | ||
| Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. | Q44455371 | ||
| Liver transplantation for nonalcoholic steatohepatitis: the new epidemic | Q44777597 | ||
| Metformin in the treatment of patients with non-alcoholic steatohepatitis | Q44778658 | ||
| Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis | Q44880772 | ||
| Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease | Q45299361 | ||
| Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. | Q45962265 | ||
| Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways | Q46084689 | ||
| De novo nonalcoholic fatty liver disease after liver transplantation | Q46201190 | ||
| Successful management of a type 2 diabetic donor in living-donor liver transplantation: a case report | Q46310921 | ||
| Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction | Q46432992 | ||
| Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis | Q46620387 | ||
| The impact of disease recurrence on graft survival following liver transplantation: a single centre experience | Q46787456 | ||
| Carotid artery intima-media thickness in nonalcoholic fatty liver disease | Q46814273 | ||
| Recurrence of non-alcoholic steatohepatitis after liver transplantation in a 13-yr-old boy. | Q46970907 | ||
| Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis | Q47394340 | ||
| Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation | Q47960515 | ||
| Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. | Q51327702 | ||
| Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. | Q51442516 | ||
| Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. | Q51500156 | ||
| Responses of insulin to oral glucose and fructose loads in marginally copper-deficient rats fed starch or fructose. | Q51580642 | ||
| Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. | Q53272521 | ||
| Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: Time to reconsider immunosuppression regimens? | Q56830090 | ||
| P433 | issue | 9 | |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 728-737 | |
| P577 | publication date | 2015-08-11 | |
| P1433 | published in | Clinical Transplantation | Q15754920 |
| P1476 | title | Non-alcoholic fatty liver disease following liver transplantation: a clinical review | |
| P478 | volume | 29 |
| Q91841255 | A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH) |
| Q64286286 | A structured literature review of interventions used in the management of nonalcoholic steatohepatitis ( NASH ) |
| Q33779040 | Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience |
| Q92089595 | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
| Q28079900 | NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? |
| Q97425388 | Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation |
Search more.